Related Experiment Video
Updated: Mar 8, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Debilitating Skin Toxicity Associated with Pembrolizumab Therapy in an 81-Year-Old Female with Malignant Melanoma
Muhammad O Khokhar1, Jacob Kettle2, Amruth R Palla1
1Division of Hematology and Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri Columbia, Columbia, MO, USA.
Abstract:
Frequently described immune-mediated adverse effects of immune therapy include dermatological complications, hepatitis, colitis, pneumonitis, and endocrinopathies. As utilization of pembrolizumab and related agents continues to expand both in the available indications as well as duration of exposure, there remains a significant potential to uncover previously undescribed adverse events. From a dermatological standpoint, 39% of patients receiving pembrolizumab therapy experience some form of skin-related drug toxicity [Naidoo et al.: Ann Oncol 2015;26: 2375-2391]. We describe a case of pembrolizumab-induced disabling autoimmune ectodermal toxicity.
More Related Videos
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
04:12Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA
Published on: December 19, 2019
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against...